16
total announcements
SPARC.NS · 15 min delayed
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has filed an application with the stock exchanges seeking reclassification from the 'Promoter Group' category to the 'Public' category, in accordance with SEBI regulations.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has informed the Exchange about the publication of unaudited financial results for the first quarter ended June 30, 2026, in the Financial Express newspaper.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has held its 21st Annual General Meeting on August 10, 2026, where all resolutions were passed with a requisite majority. The meeting was conducted through video conferencing, and the Chairman's speech was delivered. The company secretary has informed the exchange that the voting results will be submitted to the stock exchanges within two working days and will be placed on the company's website.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has informed the Exchange about Monitoring Agency Report for the quarter ended June 30, 2026. The report has been issued by Acuité Ratings & Research Limited, the Monitoring Agency appointed by the Company to monitor the utilization of the proceeds raised from the said issue.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has announced its unaudited financial results for the quarter ended June 30, 2026, and has approved the reclassification of certain promoter group individuals from the 'Promoter Group' category to the 'Public' category.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, which were approved by the Board of Directors. The results include revenue from operations and other operating revenue. The Board also approved the reclassification of certain promoter group individuals from the 'Promoter Group' category to the 'Public' category.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has received requests from two shareholders, Sudhir Vrundavandas Valia and his family members, to reclassify their status from 'Promoter Group' to 'Public' category under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company will examine the requests in accordance with the applicable provisions and place them before the Board of Directors for consideration.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has informed the Exchange about Copy of Newspaper Publication related to the 21st Annual General Meeting of the Company and other related information.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 10, 2026 along with the Annual Report for FY 2025-26.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding Change in Director(s) of the company. Dr. Rajamannar Thennati retires from the Board of Directors upon completion of his term, and Mr. Anil Raghavan is appointed as Managing Director and Chief Executive Officer with effect from August 11, 2026.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has informed the Exchange about the publication of a newspaper advertisement regarding the 21st Annual General Meeting of the Company and other related information. The company has recommended a final dividend of 7.3 per equity share of face value of ₹ 5 each (i.e. 60 percent) for the financial year 2025-2026.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding the 21st Annual General Meeting of the Company, to be held on August 10, 2026, through Video Conference/OAVM, with the Annual Report and Notice available on the company's website.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has received a confirmation certificate under SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026, indicating that securities received for dematerialization were confirmed and listed on stock exchanges.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has informed the Exchange about change in Management, with Ms. Shanta Gupta and Dr. Nitin Dharmadhikari retiring and Mr. Prasanna Deshmukh appointed as Functional Head – Human Resources & Administration.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has informed the Exchange about the termination of a license agreement with CMS Bridging DMCC. The agreement was for the development and commercialization of multiple products in Mainland China, Hong Kong, Macao, and Taiwan. The termination has no material impact on the company's financial position, operations, or other activities.
Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited has closed its trading window due to the declaration of unaudited financial results for the quarter ended June 30, 2026. The trading window will remain closed for 48 hours after the declaration.